AZTA · Azenta, Inc.
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Cap structure and valuation
| Cap structure | |
|---|---|
| SP | $26.39 |
| SO | 46.1M |
| Options | 0.0M |
| Warrants | 0.0M |
| FD SO | 46.1M |
| MC | $1.22B |
| Cash | $234.0M |
| Total debt | — |
| EV | $982.4M |
| TTM Multiples | |
|---|---|
| EV / Revenue | 1.6x |
| EV / EBITDA | — |
| MC / Net Income | — |
| EV / FCF | — |
| MC / FCF | — |
| Ownership & coverage | |
|---|---|
| Institutional | 116.9% |
| Insiders | 1.0% |
| # Institutions | 354 |
| Analysts | 5 |
| Consensus | Buy |
| Avg target | $26.20 |
| Short % float | 21.2% |
| Days to cover | 7.12 |
MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-04. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.
Financial statements
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Total Revenue | 144.79 | 148.64 | 159.19 | 143.85 |
| Revenue YoY % | 1.0% | 0.8% | 5.7% | (0.3%) |
| Cost of Revenue | 82.76 | 84.94 | 86.92 | 77.45 |
| Gross Profit | 62.03 | 63.71 | 72.27 | 66.40 |
| Gross Profit YoY % | (1.2%) | (7.4%) | 5.5% | 2.8% |
| Gross Margin % | 42.8% | 42.9% | 45.4% | 46.2% |
| SG&A | 67.89 | 60.61 | 61.71 | 60.08 |
| R&D | 9.43 | 9.19 | 8.26 | 7.42 |
| Operating Expense | 227.82 | 70.94 | 70.37 | 68.25 |
| Operating Income | (165.79) | (7.24) | 1.90 | (1.85) |
| Operating Income YoY % | (811.2%) | 16.8% | 141.0% | 74.0% |
| Operating Margin % | (114.5%) | (4.9%) | 1.2% | (1.3%) |
| EBITDA | — | 6.41 | 16.34 | 12.87 |
| EBITDA Margin % | — | 4.3% | 10.3% | 8.9% |
| Other Income / (Expense) | 4.67 | (5.07) | 3.62 | (43.50) |
| Pretax Income | (161.12) | (12.30) | 5.52 | (45.35) |
| Tax Provision | (0.32) | 3.13 | (45.35) | 2.63 |
| Net Income | (160.80) | (15.43) | 50.88 | (47.99) |
| Net Margin % | (111.1%) | (10.4%) | 32.0% | (33.4%) |
| Diluted EPS | -$3.49 | -$0.34 | $1.11 | -$1.05 |
| Basic EPS | -$3.49 | -$0.34 | $1.11 | -$1.05 |
| Diluted Avg Shares | 46.1 | 45.9 | 46.0 | 45.8 |
| Basic Avg Shares | 46.1 | 45.9 | 45.8 | 45.8 |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Total Revenue | 596.48 | 593.82 | 573.45 | 665.07 | 555.50 |
| Revenue YoY % | 0.4% | 3.6% | (13.8%) | 19.7% | — |
| Cost of Revenue | 332.06 | 323.54 | 318.83 | 401.93 | 299.91 |
| Gross Profit | 264.42 | 270.28 | 254.62 | 263.14 | 255.58 |
| Gross Profit YoY % | (2.2%) | 6.1% | (3.2%) | 3.0% | — |
| Gross Margin % | 44.3% | 45.5% | 44.4% | 39.6% | 46.0% |
| SG&A | 250.29 | 261.56 | 262.96 | 316.28 | 251.47 |
| R&D | 34.30 | 30.39 | 31.52 | 33.96 | 27.54 |
| Operating Expense | 437.39 | 297.12 | 305.91 | 336.27 | 280.32 |
| Operating Income | (172.98) | (26.84) | (51.28) | (73.13) | (24.73) |
| Operating Income YoY % | (544.4%) | 47.7% | 29.9% | (195.6%) | — |
| Operating Margin % | (29.0%) | (4.5%) | (8.9%) | (11.0%) | (4.5%) |
| EBITDA | — | 34.37 | 39.46 | 12.46 | 28.97 |
| EBITDA Margin % | — | 5.8% | 6.9% | 1.9% | 5.2% |
| Interest Expense | — | — | — | — | 4.59 |
| Other Income / (Expense) | (40.27) | (60.52) | (108.37) | 41.32 | 2,163.53 |
| Pretax Income | (213.25) | (87.36) | (159.66) | (31.81) | 2,134.21 |
| Tax Provision | (39.91) | (31.60) | 5.24 | (17.55) | 1.35 |
| Net Income | (173.34) | (55.76) | (164.90) | (14.26) | 2,132.86 |
| Net Margin % | (29.1%) | (9.4%) | (28.8%) | (2.1%) | 384.0% |
| Diluted EPS | -$3.77 | -$1.22 | -$3.10 | -$0.22 | $28.48 |
| Basic EPS | -$3.77 | -$1.22 | -$3.10 | -$0.22 | $28.48 |
| Diluted Avg Shares | 46.1 | 45.9 | 53.2 | 66.3 | 74.9 |
| Basic Avg Shares | 46.1 | 45.7 | 53.2 | 66.3 | 74.9 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Cash & Equivalents | 234.03 | 336.63 | 279.78 | 270.04 |
| Short-term Investments | 146.48 | 73.03 | 61.14 | 48.82 |
| Receivables | 131.32 | 142.27 | 142.18 | 124.53 |
| Inventory | 78.51 | 82.46 | 74.96 | 80.85 |
| Other Current Assets | 136.64 | 145.52 | 150.28 | 154.10 |
| Total Current Assets | 726.99 | 779.90 | 708.34 | 678.34 |
| Net PPE | 171.83 | 152.03 | 153.95 | 153.64 |
| Operating Lease ROU | 59.45 | 57.75 | 54.05 | 60.66 |
| Goodwill | 553.07 | 702.56 | 702.39 | 703.61 |
| Intangible Assets | 91.43 | 96.60 | 101.81 | 108.14 |
| Other Assets | 301.12 | 285.59 | 339.03 | 314.61 |
| Total Assets | 1,903.89 | 2,074.43 | 2,059.58 | 2,019.00 |
| Accounts Payable | 33.14 | 38.77 | 37.72 | 38.32 |
| Current Lease Liabilities | — | — | 7.17 | — |
| Other Current Liabilities | 224.06 | 228.45 | 192.78 | 207.85 |
| Total Current Liabilities | 257.19 | 267.21 | 237.67 | 246.17 |
| Long-term Lease Liabilities | 55.71 | 54.46 | 51.24 | 52.63 |
| Other Liabilities | 36.31 | 37.93 | 43.68 | 47.18 |
| Total Liabilities | 349.21 | 359.60 | 332.60 | 345.98 |
| Retained Earnings | 1,243.73 | 1,404.52 | 1,419.96 | 1,369.08 |
| Total Equity | 1,554.68 | 1,714.83 | 1,726.99 | 1,673.02 |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 234.03 | 279.78 | 280.03 | 678.91 | 658.27 |
| Short-term Investments | 146.48 | 61.14 | 151.16 | 338.87 | 911.76 |
| Receivables | 131.32 | 142.18 | 154.17 | 156.53 | 163.76 |
| Inventory | 78.51 | 74.96 | 71.32 | 128.20 | 85.54 |
| Other Current Assets | 136.64 | 150.28 | 176.35 | 116.44 | 640.01 |
| Total Current Assets | 726.99 | 708.34 | 833.03 | 1,418.96 | 2,459.35 |
| Net PPE | 171.83 | 153.95 | 155.62 | 205.74 | 154.47 |
| Operating Lease ROU | 59.45 | 54.05 | 60.41 | 66.58 | 54.06 |
| Goodwill | 553.07 | 702.39 | 691.41 | 784.34 | 513.62 |
| Intangible Assets | 91.43 | 101.81 | 125.04 | 294.30 | 178.40 |
| Other Assets | 301.12 | 339.03 | 234.75 | 115.80 | 356.22 |
| Total Assets | 1,903.89 | 2,059.58 | 2,100.26 | 2,885.72 | 3,716.12 |
| Accounts Payable | 33.14 | 37.72 | 33.34 | 35.80 | 38.65 |
| Current Lease Liabilities | — | 7.17 | 8.09 | 9.50 | 6.92 |
| Other Current Liabilities | 224.06 | 192.78 | 164.66 | 165.63 | 184.97 |
| Total Current Liabilities | 257.19 | 237.67 | 206.09 | 210.93 | 230.55 |
| Long-term Lease Liabilities | 55.71 | 51.24 | 56.68 | 60.44 | 49.23 |
| Other Liabilities | 36.31 | 43.68 | 69.65 | 79.86 | 72.96 |
| Total Liabilities | 349.21 | 332.60 | 332.42 | 351.22 | 352.74 |
| Retained Earnings | 1,243.73 | 1,419.96 | 1,475.72 | 1,641.01 | 1,655.36 |
| Total Equity | 1,554.68 | 1,726.99 | 1,767.85 | 2,534.50 | 3,363.39 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Net Income | (160.80) | (15.43) | 50.88 | (47.99) |
| D&A | — | 13.65 | 14.43 | 14.72 |
| Stock-Based Comp | 6.27 | 4.06 | 4.17 | 3.26 |
| Δ Working Cap & Other | — | 18.57 | (67.31) | 55.81 |
| Operating Cash Flow | — | 20.85 | 2.17 | 25.81 |
| CapEx | — | (6.19) | (7.86) | (10.84) |
| Other Investing | — | 42.96 | 8.69 | (18.86) |
| Investing Cash Flow | — | 36.77 | 0.83 | (29.70) |
| Stock Issuance | — | — | 1.22 | 0.00 |
| Stock Buyback | — | — | 0.00 | 0.00 |
| Other Financing | — | (2.63) | — | — |
| Financing Cash Flow | — | (2.63) | 0.82 | (0.13) |
| Free Cash Flow | — | 14.65 | (5.69) | 14.97 |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Net Income | (173.34) | (55.76) | (164.90) | (14.26) | 2,132.86 |
| D&A | — | 61.21 | 90.74 | 85.58 | 53.70 |
| Stock-Based Comp | 17.75 | 20.88 | 14.47 | 9.38 | 10.67 |
| Δ Working Cap & Other | — | 45.85 | 109.43 | (63.21) | (2,663.27) |
| Operating Cash Flow | — | 72.18 | 49.74 | 17.49 | (466.05) |
| CapEx | — | (33.86) | (37.39) | (39.44) | (73.44) |
| Acquisitions | — | 0.00 | 0.00 | (386.51) | (125.88) |
| Other Investing | — | (56.60) | 262.13 | 857.33 | 1,664.90 |
| Investing Cash Flow | — | (90.46) | 224.74 | 431.38 | 1,465.59 |
| Debt Repayment | — | — | 0.00 | 0.00 | (49.73) |
| Stock Issuance | — | 2.77 | 3.28 | 3.62 | 5.25 |
| Stock Buyback | — | 0.00 | (661.70) | (838.51) | 0.00 |
| Dividends Paid | — | — | 0.00 | 0.00 | (7.49) |
| Other Financing | — | (12.36) | — | (9.19) | (10.79) |
| Financing Cash Flow | — | (9.59) | (659.21) | (844.08) | (62.76) |
| Free Cash Flow | — | 38.32 | 12.35 | (21.95) | (539.48) |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Current Ratio | 2.83 | 2.92 | 2.98 | 2.76 |
| Quick Ratio | 2.52 | 2.61 | 2.66 | 2.43 |
| Debt / Equity | 0.22 | 0.21 | 0.19 | 0.21 |
| EBITDA Margin % | — | 4.3% | 10.3% | 8.9% |
| Working Capital | 469.79 | 512.69 | 470.67 | 432.17 |
| Net Debt | — | — | — | — |
| ROE % | (10.3%) | (0.9%) | 2.9% | (2.9%) |
| ROA % | (8.4%) | (0.7%) | 2.5% | (2.4%) |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Current Ratio | 2.83 | 2.98 | 4.04 | 6.73 | 10.67 |
| Quick Ratio | 2.52 | 2.66 | 3.70 | 6.12 | 10.30 |
| Debt / Equity | 0.22 | 0.19 | 0.19 | 0.14 | 0.10 |
| EBITDA Margin % | — | 5.8% | 6.9% | 1.9% | 5.2% |
| Working Capital | 469.79 | 470.67 | 626.94 | 1,208.03 | 2,228.80 |
| Net Debt | — | — | — | — | — |
| ROE % | (11.1%) | (3.2%) | (9.3%) | (0.6%) | 63.4% |
| ROA % | (9.1%) | (2.7%) | (7.9%) | (0.5%) | 57.4% |
Insider activity (last 2 years)
| Date Filed | Reporter | Relationship | Trans. Date | Code | Shares | Price | Total Value |
|---|---|---|---|---|---|---|---|
| 2026-05-19 | Cornog William L | Director | 2026-05-18 | P | 10,000 | $16.38 | $163,800 |
| 2026-05-18 | Starr Ephraim | Officer (SVP, Gen Counsel & Secretary) | 2026-05-15 | F | (3,621) | $16.02 | -$58,008 |
| 2026-05-12 | Koffey Quentin | Director | 2026-02-05 | A | 5,663 | — | $0 |
| 2026-04-30 | MARTIN WILLIAM E. III | Officer (President Multiomics) | 2026-04-28 | A | 17,790 | $24.24 | $431,230 |
| 2026-02-06 | Nova Tina Susan | Director | 2026-02-06 | A | 5,663 | $27.85 | $157,715 |
| 2026-02-06 | Cornog William L | Director | 2026-02-05 | A | 5,663 | — | $0 |
| 2026-02-06 | Madaus Martin D | Director | 2026-02-05 | A | 5,663 | — | $0 |
| 2026-02-06 | Doshi Dipal | Director | 2026-02-05 | A | 5,663 | $27.85 | $157,715 |
| 2026-02-06 | Casal Frank | Director | 2026-02-05 | A | 7,243 | $27.85 | $201,718 |
| 2026-02-06 | McLaughlin Erica | Director | 2026-02-05 | A | 5,663 | $27.85 | $157,715 |
| 2026-02-06 | Davis Robyn C | Director | 2026-02-05 | A | 5,663 | — | $0 |
| 2025-12-03 | Marotta John | Director, Officer (President and CEO) | 2025-11-24 | A | 118,194 | — | $0 |
| 2025-11-25 | Marotta John | Director, Officer (President and CEO) | 2025-11-24 | A | 122,269 | — | $0 |
| 2025-11-25 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2025-11-24 | A | 36,681 | — | $0 |
| 2025-11-25 | Pirogova Olga | Officer (SVP and CHRO) | 2025-11-24 | A | 16,303 | — | $0 |
| 2025-11-25 | Zhou Ginger | Officer (SVP and GM, Multiomics) | 2025-11-24 | A | 13,042 | — | $0 |
| 2025-11-25 | Starr Ephraim | Officer (SVP, Gen Counsel & Secretary) | 2025-11-24 | A | 34,235 | — | $0 |
| 2025-11-25 | Cornog William L | Director | 2025-05-20 | P | 2,748 | $27.37 | $75,213 |
| 2025-11-25 | Cornog William L | Director | 2025-05-19 | P | 4,152 | $26.98 | $112,021 |
| 2025-11-25 | Cornog William L | Director | 2025-05-16 | P | 100 | $26.50 | $2,650 |
| 2025-11-17 | Zhou Ginger | Officer (SVP and GM, Multiomics) | 2025-11-14 | F | (1,118) | $29.75 | -$33,260 |
| 2025-11-17 | Pirogova Olga | Officer (SVP and CHRO) | 2025-11-14 | F | (1,553) | $29.75 | -$46,202 |
| 2025-11-17 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2025-11-14 | F | (3,039) | $29.75 | -$90,410 |
| 2025-11-17 | Marotta John | Director, Officer (President and CEO) | 2025-11-14 | F | (10,980) | $29.75 | -$326,655 |
| 2025-11-14 | Pirogova Olga | Officer (SVP and CHRO) | 2025-08-12 | S | (1,085) | $28.54 | -$30,966 |
| 2025-11-14 | Zhou Ginger | Officer (SVP and GM, Multiomics) | 2025-08-12 | S | (1,085) | $28.54 | -$30,966 |
| 2025-11-14 | Marotta John | Director, Officer (President and CEO) | 2025-06-02 | P | 1,000 | $25.99 | $25,990 |
| 2025-11-14 | Malus Alan J | Director | 2025-05-30 | P | 12,000 | $26.65 | $319,800 |
| 2025-09-12 | Marotta John | Director, Officer (President and CEO) | 2025-09-10 | S | (316) | $29.41 | -$9,294 |
| 2025-08-13 | Zhou Ginger | Officer (SVP and GM, Multiomics) | 2025-08-12 | D | (1,085) | $28.54 | -$30,966 |
| 2025-08-13 | Pirogova Olga | Officer (SVP and CHRO) | 2025-08-12 | D | (1,085) | $28.54 | -$30,966 |
| 2025-08-12 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2025-08-11 | P | 2,500 | $27.96 | $69,900 |
| 2025-06-04 | Marotta John | Director, Officer (President and CEO) | 2025-06-02 | A | 1,000 | $25.99 | $25,990 |
| 2025-06-04 | Marotta John | Director, Officer (President and CEO) | 2025-05-09 | A | 1,796 | $27.49 | $49,377 |
| 2025-06-04 | Marotta John | Director, Officer (President and CEO) | 2025-05-08 | A | 3,637 | $27.49 | $99,999 |
| 2025-06-03 | Malus Alan J | Director | 2025-05-30 | A | 12,000 | $26.65 | $319,800 |
| 2025-05-27 | Starr Ephraim | Officer (SVP, Gen Counsel & Secretary) | 2025-05-15 | A | 37,779 | $26.71 | $1,009,077 |
| 2025-05-20 | Cornog William L | Director | 2025-05-20 | A | 2,748 | $27.37 | $75,213 |
| 2025-05-20 | Cornog William L | Director | 2025-05-19 | A | 4,152 | $26.98 | $112,021 |
| 2025-05-20 | Cornog William L | Director | 2025-05-16 | A | 100 | $26.50 | $2,650 |
| 2025-05-12 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2025-05-09 | A | 4,000 | $27.49 | $109,960 |
| 2025-05-12 | Marotta John | Director, Officer (President and CEO) | 2025-05-09 | A | 1,796 | $27.84 | $50,005 |
| 2025-05-12 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2025-05-08 | A | 2,000 | $27.67 | $55,340 |
| 2025-05-12 | Marotta John | Director, Officer (President and CEO) | 2025-05-08 | A | 3,637 | $27.49 | $99,999 |
| 2025-02-13 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2025-02-11 | A | 2,200 | $46.00 | $101,200 |
| 2025-02-11 | Koffey Quentin | Director | 2025-02-07 | A | 4,040 | — | $0 |
| 2025-02-11 | Malus Alan J | Director | 2025-02-07 | A | 4,040 | $52.32 | $211,373 |
| 2025-02-11 | Casal Frank | Director | 2025-02-07 | A | 5,168 | $52.32 | $270,390 |
| 2025-02-11 | Davis Robyn C | Director | 2025-02-07 | A | 4,040 | $52.32 | $211,373 |
| 2025-02-11 | Nova Tina Susan | Director | 2025-02-07 | A | 4,040 | $52.32 | $211,373 |
| 2025-02-11 | Madaus Martin D | Director | 2025-02-07 | A | 4,040 | — | $0 |
| 2025-02-11 | Doshi Dipal | Director | 2025-02-07 | A | 4,040 | $52.32 | $211,373 |
| 2025-02-11 | Cornog William L | Director | 2025-02-07 | A | 4,040 | — | $0 |
| 2025-02-11 | McLaughlin Erica | Director | 2025-02-07 | A | 4,040 | $52.32 | $211,373 |
| 2025-02-04 | Hughes Violetta | Officer (VP, Chief Accounting Officer) | 2025-02-03 | S | (317) | $52.97 | -$16,791 |
| 2025-02-04 | Zhou Ginger | Officer (SVP and General Manager, Genom) | 2025-01-31 | P | 417 | $45.88 | $19,132 |
| 2024-12-09 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2024-12-05 | A | 23,045 | $45.00 | $1,037,025 |
| 2024-12-09 | Lin Lawrence Y. | Officer (EVP, CFO and Treasurer) | 2024-12-05 | A | 5,768 | $45.00 | $259,560 |
| 2024-12-05 | Wang David Dong | Officer (SVP & GM, SMS) | 2024-12-04 | D | (140) | $46.65 | -$6,531 |
| 2024-11-21 | Pirogova Olga | Officer (SVP and CHRO) | 2024-11-19 | S | (548) | $40.07 | -$21,958 |
| 2024-11-21 | Hughes Violetta | Officer (VP, Chief Accounting Officer) | 2024-11-19 | S | (163) | $40.07 | -$6,531 |
| 2024-11-21 | Zhou Ginger | Officer (SVP and General Manager, Genom) | 2024-11-19 | S | (491) | $40.07 | -$19,674 |
| 2024-11-21 | Wang David Dong | Officer (SVP & GM, SMS) | 2024-11-19 | S | (348) | $40.07 | -$13,944 |
| 2024-11-21 | Joseph Jason | Officer (SVP, General Counsel, Secy.) | 2024-11-19 | S | (1,139) | $40.07 | -$45,640 |
| 2024-11-21 | Cueto Herman | Officer (EVP, Chief Financial Officer) | 2024-11-19 | S | (712) | $40.07 | -$28,530 |
| 2024-11-19 | Marotta John | Director, Officer (President and CEO) | 2024-11-19 | P | 1,250 | $40.67 | $50,838 |
| 2024-11-19 | Madaus Martin D | Director | 2024-11-19 | P | 4,940 | $40.77 | $201,404 |
| 2024-11-19 | Marotta John | Director, Officer (President and CEO) | 2024-11-18 | P | 12,716 | $39.48 | $502,066 |
| 2024-11-19 | Cornog William L | Director | 2024-11-18 | P | 12,500 | $39.60 | $495,000 |
| 2024-11-19 | HIRSCH DIDIER | Director | 2024-11-18 | P | 1,000 | $39.50 | $39,500 |
| 2024-11-19 | Marotta John | Director, Officer (President and CEO) | 2024-11-15 | A | 83,622 | $41.51 | $3,471,149 |
| 2024-11-19 | Pirogova Olga | Officer (SVP and CHRO) | 2024-11-15 | A | 10,381 | $41.51 | $430,915 |
| 2024-11-19 | Joseph Jason | Officer (SVP, General Counsel, Secy.) | 2024-11-15 | A | 13,841 | $41.51 | $574,540 |
| 2024-11-19 | Hughes Violetta | Officer (VP, Chief Accounting Officer) | 2024-11-15 | A | 6,921 | $41.51 | $287,291 |
| 2024-11-19 | Wang David Dong | Officer (SVP & GM, SMS) | 2024-11-15 | A | 8,651 | $41.51 | $359,103 |
| 2024-11-19 | Zhou Ginger | Officer (SVP and General Manager, Genom) | 2024-11-15 | A | 8,651 | $41.51 | $359,103 |
| 2024-11-14 | Malus Alan J | Director | 2024-11-06 | D | 995 | $46.52 | $46,287 |
| 2024-11-08 | Cornog William L | Director | 2024-11-06 | D | (995) | $46.52 | -$46,287 |
| 2024-11-08 | Koffey Quentin | Director | 2024-11-06 | A | 995 | — | $0 |
| 2024-10-21 | Cueto Herman | Officer (EVP, Chief Financial Officer) | 2024-10-17 | S | (1,595) | $43.68 | -$69,670 |
| 2024-09-11 | Marotta John | Director, Officer (President and CEO) | 2024-09-09 | A | 3,273 | $46.15 | $151,049 |
| 2024-08-13 | Cueto Herman | Officer (EVP, Chief Financial Officer) | 2024-08-09 | A | 11,309 | $55.27 | $625,048 |
| 2024-08-13 | Wang David Dong | Officer (SVP & GM, SMS) | 2024-08-09 | A | 6,333 | $55.27 | $350,025 |
| 2024-08-13 | Pirogova Olga | Officer (SVP and CHRO) | 2024-08-09 | A | 6,333 | $55.27 | $350,025 |
| 2024-08-13 | Joseph Jason | Officer (SVP, General Counsel, Secy.) | 2024-08-09 | A | 10,856 | $55.27 | $600,011 |
| 2024-08-13 | Zhou Ginger | Officer (SVP and General Manager, Genom) | 2024-08-09 | A | 6,333 | $55.27 | $350,025 |
| 2024-08-02 | Zhou Ginger | Officer (SVP and General Manager, Genom) | 2024-01-31 | A | 64 | $53.01 | $3,393 |
| 2024-08-02 | Vacha Robin | Officer (SVP, GM Life Science Products) | 2024-01-31 | A | 151 | $53.01 | $8,005 |
| 2024-08-01 | Joseph Jason | Officer (SVP, General Counsel, Secy.) | 2024-08-01 | D | (1,000) | $62.05 | -$62,050 |
| 2024-07-29 | Joseph Jason | Officer (SVP, General Counsel, Secy.) | 2024-07-25 | D | (3,000) | $60.00 | -$180,000 |
| 2024-05-22 | Hughes Violetta | Officer (VP, Chief Accounting Officer) | 2024-05-20 | D | (584) | $51.36 | -$29,994 |